Today we are going to look at what investors should expect from Valens’ second-quarter results. Analysts are expecting revenue to come in at $6.7M with a net loss of 1.2M. Management has also provided some revenue guidance. In its Q1/19 MD&A, the Company announced that it had processed ~5,000 kg of biomass in the first 55 days of Q2, implying that VGW is expecting to process 8,200 kg during the second quarter. Valens GroWorks generated $2.2M in revenue on 1,800 kg of biomass processed in Q1, and presuming it maintains a similar run-rate, Valens could generate up to $9.9M in revenue based on 8,200 kg processed in Q2/19. On July 10, 2019, Valens GroWorks up-listed and began trading on the Toronto Venture Exchange (TSXV).

Win Big With Our Small Cap Picks

Leave this field empty if you're human:

Robust client base of Canadian cultivators supports future revenue growth. Valens has signed toll processing extraction agreements with five of the Top 10 licensed cultivators by market cap, including The Green Organic Dutchman (TSX:TGOD), Organigram (TSXV:OGI), Tilray (NASDAQ:TRLY), Canopy Growth (TSX:WEED), and HEXO Corp. (TSX:HEXO). The HEXO and TGOD contracts are for a minimum of 30,000 kg of biomass in the first year and a minimum of 50,000 kg in the second year, while the TLRY agreement is for a minimum of 60,000 kg over two years. The Company announced on June 18, 2019, that it plans to expand its annual extraction capacity from 240,000 kg to 425,000 kg, with plans to increase to 1,000,000 kg once the Company builds out the rest of facility by Q2/20. The expansion of extraction capacity is expected to add further revenue potential as the Company can bid on more extraction agreements.

Ready for legalization of derivatives and edibles. Valens GroWorks can offer cultivators four different types of extraction methods (CO2, ethanol, hydrocarbon, and solvent-less). With this wide selection of extraction methods VGW can develop a wide variety of products and formulations for its partners, including oils, capsules, vape pens, wax, shatter, butter, and live resin. In addition, Valens GroWorks has a partnership with Sorse Emulsion Technology for exclusive Canadian rights to a proprietary formula for a cannabis beverage. The beverage is expected to be shelf stable, with zero cannabis taste and colour, and a 5 to 15 minute onset time with a 45 minute to 2 hour offset time, designed to mimic an alcoholic beverage.

Looking ahead. With a total of 10 toll processing agreements, Valens GroWorks has clear revenue visibility for the next two years and is ready for the legalization of derivatives and edibles. The additional extraction capacity will enable Valens to enter into further agreements with more cultivators, which is expected to drive revenue growth.

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below:

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflic